Adult Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes.
The study will last approximately 47 weeks and may include about 12 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participant must have type 2 diabetes mellitus (T2DM)
-Participant must have HbA1c between >7.0% and <10.5%
-Participant must be on stable treatment dose of metformin
-Participant must be of stable weight
-Participant must not have type 1 diabetes
-Participant must not have pancreatitis
-Participant must not have disorders with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
-Participant must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
-Participant must not have had a heart attack stroke, or hospitalization for congestive heart failure in the past 2 months
-Participant must not have been taking weight loss drugs including over-the-counter medications during the last 3 months